Shanghai-based drug developer Allist Pharmaceuticals has raised RMB1.2 billion ($171 million) in a Series A round of funding led by Shiyu Capital. Other participants include Loyal Valley Capital and Suzhou Industrial Park Bioventure Investment.
Established in 2004, the company focuses on treatments for tumours and diabetes. It has launched two drugs so far - one for stomach diseases and the other for high blood pressure. It has a further eight...
Newlink Group, operator of a platform that helps drivers in China locate the best value gas stations, has raised a RMB900 million ($128 million) Series D round led by China Capital Investment Group. Xiaomi Corporation also participated.
Chinese biotech start-up Harbour BioMed has raised $102.8 million in Series C funding. It comes four months after it closed an extended Series B round of $75 million.
Vietnam’s VinaCapital and Japan’s Daiwa PI Partners are poised to make a partial exit from Vietnamese dairy producer International Dairy Products (IDP).
BlueCity Holdings, the VC-backed holding company for Chinese gay dating platform Blued, traded strongly after raising $84.8 million through a NASDSAQ IPO.